FDA greenlights GSK’s drug for UTIs in women and girls
The FDA approved GSK’s drug for a common type of urinary tract infection (UTI) in women and adolescent girls, one of five new ...
US FDA greenlights GSK's drug for UTIs in women and girls
The U.S. Food and Drug Administration on Tuesday approved GSK's drug for a common type of urinary tract infection (UTI) in ...
Exploring Unmet Needs In Chronic Hepatitis B: Understanding The Disease, Its Impact And The Potential Of Functional Cure
While acute hepatitis B infection is often resolved by the immune system, CHB occurs when the body's defences are unable to ...
US FDA approves GSK's 'Blujepa' for treating UTIs in women and girls
The approval was based on data from two late-stage trials showing the drug was superior to nitrofurantoin, the ...
PMLive2d
GSK’s antibiotic Blujepa granted FDA approval to treat urinary tract infections
GSK’s oral antibiotic Blujepa (gepotidacin) has been approved by the US Food and Drug Administration (FDA) to treat ...
MedPage Today on MSN9h
STRIDE: Semaglutide Shows it Has Legs in Peripheral Artery Disease
CHICAGO -- Semaglutide further solidified its efficacy for diabetes-associated cardiovascular conditions, this time building ...
PharmExec3d
FDA Approves GSK’s Blujepa for Uncomplicated Urinary Tract Infections
Blujepa marks the first new oral antibiotic to gain FDA approval for uncomplicated urinary tract infections in nearly 30 ...
‘I’m not trying to turn GSK into Google’: How GSK’s Silicon Valley veteran has transformed the pharma giant into a tech powerhouse
For much of her early career, Shobie Ramakrishnan called Silicon Valley home. GSK’s chief digital and technology officer ...
pharmaphorum4d
GSK taps into UK health data for dementia study
To test it prospectively, GSK will work with the UK Dementia Research Institute (UK DRI) and Health Data Research UK (HDR UK) ...
Medical Marketing & Media2d
Rx Rundown: Merck, Novo Nordisk, GSK and more
Merck signed a licensing agreement for a heart disease drug with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion.
New York Post3d
FDA greenlights GSK’s drug for UTIs in women and girls
While GSK has not given a sales target for Blujepa, it has said it expects the medicine, along with two other medicines in development, Brexafemme and tebipenem, to generate peak year sales of ...